Antimicrobial resistance of Gram-negative bacilli isolates from inpatients and outpatients at Yaounde Central Hospital, Cameroon

International Journal of Infectious Diseases

Volumn 8, Issue 3, 2004, Pages 147-154

  Piéboji, Joseph Gangoué ^a,b   Koulla Shiro, Sinata ^a   Ngassam, Pierre ^a   Adiogo, Dieudonné ^a   Njine, Thomas ^a   Ndumbe, Peter ^a  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antimicrobial resistance; Extended spectrum lactamase; Gram negative bacilli; Inpatients; Outpatients; Resistance phenotype

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM; CEFAZOLIN; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORINASE; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; OFLOXACIN; PENICILLINASE; PIPERACILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD; CAMEROON; CITROBACTER; CLINICAL PRACTICE; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL HYGIENE; HOSPITAL PATIENT; HUMAN; INCIDENCE; KLEBSIELLA; NONHUMAN; OUTPATIENT; PHENOTYPE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PUS; SALMONELLA; URINE;

EID: 2442476327     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2004.01.001     Document Type: Article

References (25)

1. Pfaller MA, Jones RN, Marshall SA, Coffman BL, Hollis RJ, Edmond MB, et al. Inducible AmpC β-lactamase producing Gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997;28:211-9.
2. Archibald L, Phillips L, Monnet D, Mac Govan JE, Tenover Jr F, Gaynes R. Antimicrobial resistance from inpatients and outpatients in the United States. Increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
3. Bergone-Berezin E, Decré D, Joly-Guilou ML. Opportunistic nosocomial multiply resistant bacterial, infections- their treatment and prevention. J Antimicrob Chemother 1993;32:39-47.
4. Bryce EA, Smith JA. Focused microbiological surveillance and Gram-negative β-lactamase-mediated resistance in an intensive care unit. Infect Control Hosp Epidemiol 1995;16:331-4.
5. Ho PL, Yuen KY, Yan WC, Wong Sai-Yin S, Luk WK. Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong. Hosp Infect 1995;31:305-17.
6. O'Brien TF. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clin Infect Dis 1997;24(supp 1):S2-8.
7. Farmer III JJ, Kelly MT. Enterobacteriaceae. In: Lenette EH, Balows A, Hausler WJ, Shadomy HJ, editors. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology; 1991, p. 360-83.
8. 7). Wayne, PA: National Committee for Clinical Laboratory Standards; 1997.
9. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
10. Talarmin A, Nizon JY, Cavallo JD. Pseudomonas aeruginosa et β-lactamines: mécanisme de résistance et conséquences thérapeutiques. Méd Armées 1996;24:35-9.
11. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-78.
12. e cycle, Université de Yaoundé I, 2000;p. 210.
13. Lamikamra A, Ndep RB. Trimethoprim resistance in urinary tract pathogens in two Nigerian hospitals. J Antimicrob Chemother 1989;23:151-4.
14. Philippon A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended-spectrum β-lactamases. Eur J Clin Microbiol Infect Dis 1994;13:S1-S13.
15. Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis 1997;24:S63-6.
16. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with blood stream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42:1762-70.
17. Koulla-Shiro S, Boye CS, Dosso M and the members of the Palm Project. Surveillance of antimicrobial susceptibility of Gram negative pathogens responsible for nosocomial infections in West Africa (Abstract number E-95). San Diego, California: 42nd ICAAC; 1998, p. 197.
18. Okeke IN, Lamikanra A, Edelman R. Socio-economic and behavioral factors leading to acquired bacterial, resistance to antibiotics in developing countries. Emerg Infect Dis 1999;5:18-27.
19. Eickhoff TC. Antibiotics and nosocomial infections. In: Bennett JV, Brachman PS, editors. Hospital infections. Boston: Brown & Co; 1992, p. 245-64.
20. Rice LB, Willey SH, Papanicolaou GA, Eliopoulos GM, Moellering RC, Jacoby GA. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34:2193-9.
21. Monnet DL, Archibald LK, Phillips L, Tenover FC, McGowan JE, Gaynes RP. Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modeling. Infect Control Hosp Epidemiol 1998;19:388-94.
22. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999;27:1421-8.
23. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents 2001;17:357-63.
24. Lesch CA, Itokazu GS, Danziger LH, Weinstein RA. Multi-hospital analysis of antimicrobial usage and resistance trends. Diagn Microbiol Infect Dis 2001;41:149-54.
25. Huovinen P, Sundström L, Swedberg G, Sköd O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 1995;39:279-89.